Epidarex Capital Secures $145 Million First Close for Fourth Life Sciences Fund

New updates have been reported about Epidarex Capital.

Epidarex Capital has achieved a first close of more than $145 million for its fourth fund, Epidarex Capital IV, LP, marking a significant expansion of its capacity to build early-stage life science companies across the UK and US. Anchor commitments come from the British Business Bank, Strathclyde Pension Fund, the Scottish National Investment Bank, and a group of family offices, corporates, and international investors, underscoring institutional confidence in Epidarex’s transatlantic model. Fund IV is expected to back up to 15 therapeutics and medical device start-ups originating from both established and emerging research hubs, with a focus on major unmet needs in oncology, cardiometabolic, autoimmune, and neurological diseases. Consistent with its strategy, Epidarex intends to lead early-stage financings, plug the equity gap at seed and Series A, and take an active role in shaping portfolio companies’ leadership, strategy, and progression through critical value inflection points.

Managing Partner Sinclair Dunlop said the firm sees the next three years as a particularly attractive window for backing a new wave of biotech innovation, positioning Fund IV to capture value from breakthrough science while aiming for meaningful patient and public health impact. Managing Partner Elizabeth Roper highlighted that the first close validates Epidarex’s track record in creating high-quality companies from the earliest stages and provides capital to deepen that approach and scale the Epidarex platform. For UK public investors such as the British Business Bank and the Scottish National Investment Bank, the fund aligns with national priorities to convert strong academic research into IP-rich, high-growth life science businesses. Epidarex’s existing portfolio, which includes companies such as Apellis Pharmaceuticals, Enterprise Therapeutics, Harpoon Medical, Kynos Therapeutics and Nodthera, provides a proof point for its model of building strategically valuable assets. With Fund IV, Epidarex is positioned to remain a key specialist investor in under-ventured life science markets, with implications for capital formation, innovation pipelines, and future exits across its transatlantic footprint.